B-lymphocyte subpopulations in patients with rheumatoid arthritis and the effect of an interleukin-6 receptor inhibitor on them
Герасимова Е. В., Попкова Т. В., Алексанкин А. П., Мартyнова А. В., Насонов Е. Л.
Научно-практическая ревматология
Т. 56, Вып. 6, С. 731-738
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.14412/1995-4484-2018-731-738
Аннотация:
The clinical efficacy and safety of interleukin-6 (IL-6) receptor blockade have been well studied, but the data on the impact of therapeutic inhibition of IL-6 on B cells are scarce and contradictory. Preliminary reports have shown that B cell function and a humoral immune response may be modulated by an IL-6 receptor inhibitor. Objective: to assess the effect of 12-month tocilizumab (TCZ) therapy on B-cell phenotype and gene expression in RA and to analyze the association between B-cell subsets and RA activity. Subjects and methods. Examinations were made in 24 active RA patients (20 women and 4 men) (median age, 55 [49; 64] years; disease duration, 72 [24; 108] months; DAS28 5.8 [5.3; 6.3]; the patients were seropositive for rheumatoid factor (RF) (100[%]) and for anti-cyclic citrullinated peptide antibodies (87.3[%]). The patients received TCZ 8 mg/kg every 4 weeks. After 12 months of therapy, 54[%] of patients were categorized as good responders, 46[%] as moderate responders according to t
Ключевые слова:
CD19+ B cells; Double negative B cells; Flow cytometry; Interleukin-6 receptor inhibitor; Memory B cells; Naive B cells; Rheumatoid arthritis; Tocilizumab
Язык текста: Русский
ISSN: 1995-4492
Герасимова Е. В.
Попкова Т. В.
Алексанкин А. П.
Мартyнова А. В.
Насонов Е. Л. Евгений Львович 1948-
Gerasimova E. V.
Popkova T. V.
Aleksankin A. P.
Martynova A. V.
Nasonov E. L. Evgenij L`vovich 1948-
B-lymphocyte subpopulations in patients with rheumatoid arthritis and the effect of an interleukin-6 receptor inhibitor on them
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 56, Вып. 6 С. 731-738
2018
Статья
CD19+ B cells Double negative B cells Flow cytometry Interleukin-6 receptor inhibitor Memory B cells Naive B cells Rheumatoid arthritis Tocilizumab
The clinical efficacy and safety of interleukin-6 (IL-6) receptor blockade have been well studied, but the data on the impact of therapeutic inhibition of IL-6 on B cells are scarce and contradictory. Preliminary reports have shown that B cell function and a humoral immune response may be modulated by an IL-6 receptor inhibitor. Objective: to assess the effect of 12-month tocilizumab (TCZ) therapy on B-cell phenotype and gene expression in RA and to analyze the association between B-cell subsets and RA activity. Subjects and methods. Examinations were made in 24 active RA patients (20 women and 4 men) (median age, 55 [49; 64] years; disease duration, 72 [24; 108] months; DAS28 5.8 [5.3; 6.3]; the patients were seropositive for rheumatoid factor (RF) (100[%]) and for anti-cyclic citrullinated peptide antibodies (87.3[%]). The patients received TCZ 8 mg/kg every 4 weeks. After 12 months of therapy, 54[%] of patients were categorized as good responders, 46[%] as moderate responders according to t